Anupam Rasayan India Ltd. has entered into a definitive agreement to acquire a 43.3% to 48.2% equity stake in Bliss GVS Pharma Limited. The deal, announced on May 23, 2026, aims to create an integrated global life sciences platform. The acquisition is financed through a Rs 300 crore term loan and non-controlling non-voting equity instruments, marking a significant step in the company’s strategy to expand its pharmaceutical manufacturing capabilities and global market footprint.
Strategic Expansion into Pharmaceuticals
Anupam Rasayan India Ltd. has officially announced its entry into a definitive agreement to acquire a majority stake in Bliss GVS Pharma Limited, ranging between 43.3% and 48.2%. This move includes an Open Offer to the public shareholders of the pharmaceutical company, further solidifying Anupam Rasayan’s vision of building a comprehensive integrated global life sciences and specialty pharmaceutical platform.
Deal Structure and Financials
The total purchase consideration for this strategic acquisition is structured through a combination of debt and equity instruments. The company confirmed that it has secured Rs 300 crores via a term loan, with the remaining balance being settled through the issuance of non-controlling non-voting equity instruments.
Synergy and Growth Potential
This partnership is designed to strengthen Anupam Rasayan’s presence across the entire pharmaceutical value chain, spanning from Key Starting Materials (KSMs) to finished dosage forms. By integrating Bliss GVS Pharma’s established capabilities in niche dosage forms—such as suppositories and pessaries—with Anupam Rasayan’s advanced chemistry expertise, the company expects to achieve deeper backward integration.
Bliss GVS Pharma brings a robust international footprint, particularly in Africa, Asia, and Latin America, alongside a portfolio of over 150 branded formulations. The combined platform is positioned to accelerate innovation and drive operational efficiencies across both regulated and semi-regulated markets, further enhancing its reach in Europe and the Americas.
Source: BSE
